OTC Markets OTCPK - Delayed Quote USD

Viva Biotech Holdings (VBIZF)

Compare

0.0950

-0.0732

(-43.52%)

As of January 24 at 3:00:00 PM EST. Market Open.

Currency in CNY All numbers in thousands

Download

Breakdown

TTM

12/31/2023

12/31/2022

12/31/2021

12/31/2020

Total Revenue

2,155,578.0000

2,379,631.0000

2,104,083.0000

696,958.0000

Cost of Revenue

1,417,146.0000

1,563,952.0000

1,453,102.0000

392,092.0000

Gross Profit

738,432.0000

815,679.0000

650,981.0000

304,866.0000

Operating Expense

482,307.0000

503,818.0000

381,147.0000

179,851.0000

Operating Income

256,125.0000

311,861.0000

269,834.0000

125,015.0000

Net Non Operating Interest Income Expense

-149,207.0000

-163,068.0000

-156,533.0000

-45,424.0000

Pretax Income

-55,953.0000

-459,165.0000

347,701.0000

-356,210.0000

Tax Provision

43,837.0000

45,055.0000

47,141.0000

22,660.0000

Net Income Common Stockholders

-116,113.0000

-528,475.0000

287,546.0000

-386,880.0000

Average Dilution Earnings

-174,323.0000

-124,742.0000

Diluted NI Available to Com Stockholders

-290,436.0000

-528,475.0000

162,804.0000

-386,880.0000

Basic EPS

-0.06

-0.28

0.15

-0.25

Diluted EPS

-0.14

-0.28

0.08

-0.25

Basic Average Shares

1,940,474.0000

1,915,437.0000

1,911,530.0000

1,571,507.0000

Diluted Average Shares

2,028,679.0000

1,915,437.0000

1,970,799.0000

1,571,507.0000

Total Expenses

1,899,453.0000

2,067,770.0000

1,834,249.0000

571,943.0000

Net Income from Continuing & Discontinued Operation

-116,113.0000

-528,475.0000

287,546.0000

-386,880.0000

Normalized Income

91,111.9000

-163,728.0500

229,407.6457

-494,371.0400

Interest Income

27,375.0000

21,606.0000

26,575.0000

16,710.0000

Interest Expense

176,582.0000

184,674.0000

183,108.0000

62,134.0000

Net Interest Income

-149,207.0000

-163,068.0000

-156,533.0000

-45,424.0000

EBIT

120,629.0000

-274,491.0000

530,809.0000

-294,076.0000

EBITDA

331,845.0000

-89,037.0000

683,963.0000

-223,890.0000

Reconciled Cost of Revenue

1,417,146.0000

1,563,952.0000

1,453,102.0000

392,092.0000

Reconciled Depreciation

211,216.0000

185,454.0000

153,154.0000

70,186.0000

Net Income from Continuing Operation Net Minority Interest

-116,113.0000

-528,475.0000

287,546.0000

-386,880.0000

Total Unusual Items Excluding Goodwill

-262,310.0000

-461,705.0000

67,257.0000

147,248.0000

Total Unusual Items

-262,310.0000

-461,705.0000

67,257.0000

147,248.0000

Normalized EBITDA

594,155.0000

372,668.0000

616,706.0000

-371,138.0000

Tax Rate for Calcs

0.0002

0.0001

0.0003

Tax Effect of Unusual Items

-55,085.1000

-96,958.0500

9,118.6457

39,756.9600

12/31/2020 - 9/25/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

INTS Intensity Therapeutics, Inc.

2.5474

+5.26%

LIPO Lipella Pharmaceuticals Inc.

2.7400

-2.49%

KTTA Pasithea Therapeutics Corp.

2.5200

+2.86%

GRTX Galera Therapeutics, Inc.

0.0480

+6.67%

ITOS iTeos Therapeutics, Inc.

7.73

+1.18%

LXEO Lexeo Therapeutics, Inc.

5.74

+2.87%

KRON Kronos Bio, Inc.

1.0400

0.00%

LYEL Lyell Immunopharma, Inc.

0.6402

+5.82%

IPSC Century Therapeutics, Inc.

0.8900

-1.10%

LYRA Lyra Therapeutics, Inc.

0.1892

+0.85%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Viva Biotech Holdings (VBIZF)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers